Skip to main content

AstraZeneca Enhertu breast cancer drug is recommended for EU approval

The decision was based on trial results showing that Enhertu cut the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.